acute promyelocytic leukemia
Conditions
Interventions
Case series:N/A
Sponsors
PLA 967th Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The eligibility criteria of relapsed and arsenic trioxide-resistant acute promyelocytic leukemia: ATO resistance was defined as failure to achieve HCR or progress to hematologic relapse during ATO-based therapy. Leukemia relapse was defined as one of the following: (1) 6–20% blasts and promyelocytes in bone marrow and lack of hematologic complete remission after anti-leukemia treatment, (2) > 20% blasts and promyelocytes in bone marrow, or (3) extramedullary infiltration of leukemia. Morphologic diagnosis of acute promyelocytic leukemia according to French-American-British criteria. 2.Demonstration of PML-RARa fusion transcripts by RT-PCR or cytogenetic demonstration of t(15;17)(q22;q12). 3. Eastern Cooperative Oncology Group performance status 0–3. 4. Age >18 years. 5. Normal left ventricular ejection fraction and Q-Tc interval <500 ms. 6.No history of cancer, other than basal cell skin cancer or cervical carcinoma in situ. 7.Creatinine concentration <= 3 times the institutional upper limit of normal (ULN), alanine aminotransferase and aspartate aminotransferase concentrations <= 2.5 times the ULN, and bilirubin concentration <= 2 times the ULN. 8. Written informed consent from legal guardians.
Exclusion criteria
Exclusion criteria: 1. Pregnant women or lactating women 2. Concomitant severe psychiatric condition, or patients with severe primary diseases of heart, brain, kidney and other organs. 3. Poor medication compliance, taking medicine irregularly, or taking other drugs that may affect the effect of anti-leukemia drugs. 4. Data imperfection, unable to determine efficacy and safety.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission rate;Overall Survival; | — |
Countries
China
Contacts
Public ContactChen Nannan
PLA 967th Hospital
Outcome results
None listed